Cargando…
A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF)
BACKGROUND: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, pha...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216030/ https://www.ncbi.nlm.nih.gov/pubmed/18053198 http://dx.doi.org/10.1186/1477-7827-5-45 |
_version_ | 1782149096128118784 |
---|---|
author | Alviggi, Carlo Revelli, Alberto Anserini, Paola Ranieri, Antonio Fedele, Luigi Strina, Ida Massobrio, Marco Ragni, Nicola De Placido, Giuseppe |
author_facet | Alviggi, Carlo Revelli, Alberto Anserini, Paola Ranieri, Antonio Fedele, Luigi Strina, Ida Massobrio, Marco Ragni, Nicola De Placido, Giuseppe |
author_sort | Alviggi, Carlo |
collection | PubMed |
description | BACKGROUND: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.) self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG preparation. METHODS: A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional s.c. or i.m. They started MOS with a standard hMG dose between 150–300 IU, depending upon patient's age, and underwent a standard IVF procedure. RESULTS: No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups, respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%, respectively). Pain at injection site was reported only the i.m. group (13.9% of patients). CONCLUSION: Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall safety. |
format | Text |
id | pubmed-2216030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22160302008-01-29 A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) Alviggi, Carlo Revelli, Alberto Anserini, Paola Ranieri, Antonio Fedele, Luigi Strina, Ida Massobrio, Marco Ragni, Nicola De Placido, Giuseppe Reprod Biol Endocrinol Research BACKGROUND: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.) self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG preparation. METHODS: A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional s.c. or i.m. They started MOS with a standard hMG dose between 150–300 IU, depending upon patient's age, and underwent a standard IVF procedure. RESULTS: No statistically significant difference in the mean number of collected oocytes (primary endpoint) was observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups, respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%, respectively). Pain at injection site was reported only the i.m. group (13.9% of patients). CONCLUSION: Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall safety. BioMed Central 2007-12-04 /pmc/articles/PMC2216030/ /pubmed/18053198 http://dx.doi.org/10.1186/1477-7827-5-45 Text en Copyright © 2007 Alviggi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Alviggi, Carlo Revelli, Alberto Anserini, Paola Ranieri, Antonio Fedele, Luigi Strina, Ida Massobrio, Marco Ragni, Nicola De Placido, Giuseppe A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) |
title | A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) |
title_full | A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) |
title_fullStr | A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) |
title_full_unstemmed | A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) |
title_short | A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF) |
title_sort | prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of merional (hmg-ibsa) administered subcutaneously versus merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an art programme (ivf) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216030/ https://www.ncbi.nlm.nih.gov/pubmed/18053198 http://dx.doi.org/10.1186/1477-7827-5-45 |
work_keys_str_mv | AT alviggicarlo aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT revellialberto aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT anserinipaola aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT ranieriantonio aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT fedeleluigi aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT strinaida aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT massobriomarco aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT ragninicola aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT deplacidogiuseppe aprospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT alviggicarlo prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT revellialberto prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT anserinipaola prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT ranieriantonio prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT fedeleluigi prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT strinaida prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT massobriomarco prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT ragninicola prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf AT deplacidogiuseppe prospectiverandomisedcontrolledclinicalstudyontheassessmentoftolerabilityandofclinicalefficacyofmerionalhmgibsaadministeredsubcutaneouslyversusmerionaladministeredintramuscularlyinwomenundergoingmultifollicularovarianstimulationinanartprogrammeivf |